The proposed research will analyze the role of B cells and their products in resistance to Toxoplasma gondii infection in mice. Toxoplasmosis is a significant cause of morbidity/mortality in AIDS patients and congenitally infected individuals, and is also an important reasearch tool with which to analyze innate and acquired immunological mechanisms of host resistance to pathogenic microbes. Infection of B cell-deficient muMT mice has revealed that B cells are needed in order for mice to resist chronic primary T. gondii infection and to survive challenge with highly virulent parasites if previously vaccinated. Two hypotheses are proposed to explain the role of B cells in resistance to T. gondii. The proposed experiments will examine whether B cells are needed for the production of protective antibodies or for the regulation of T. gondii-induced T cells and cytokines having the potential to cause immunopathology. Experimental goals will be addressed by analysis of host cell and cytokine responses and histopathology in infected muMT and control B cell-sufficient mice. The ability of immune serum, together with immune T cells, to confer protection against a challenge infection with virulent tachyzoites will be addressed in adoptive immunization experiments. The resistance of vaccinated mice with mutated Fc receptor genes or C3, C4, or C5 complement genes will be examined in relation to the hypothesis that antibodies are essential to protection in this model. The potential for B cells to regulate cytokine production and the generation of T. gondii-specific T cells will be studied. Also, the role of B cells in protection against congenital T. gondii infection and the influence of Toxoplasma-specific antibodies on the resistance of mice infected as neonates will be analyzed.
National Institute of Allergy and Infectious Diseases
CFDA Code
856
DUNS Number
020658969
UEI
N6K7XKLGRJ61
Project Start Date
01-April-2000
Project End Date
31-March-2005
Budget Start Date
01-April-2003
Budget End Date
31-March-2004
Project Funding Information for 2003
Total Funding
$405,003
Direct Costs
$234,106
Indirect Costs
$170,897
Year
Funding IC
FY Total Cost by IC
2003
National Institute of Allergy and Infectious Diseases
$405,003
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI046571-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI046571-04
Patents
No Patents information available for 5R01AI046571-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI046571-04
Clinical Studies
No Clinical Studies information available for 5R01AI046571-04
News and More
Related News Releases
No news release information available for 5R01AI046571-04
History
No Historical information available for 5R01AI046571-04
Similar Projects
No Similar Projects information available for 5R01AI046571-04